Author(s):
Madhuri Sanjay Wable, Adsul Samruddhi Subhash, Omkar Bapurao Bramhane, Bhand Revannath Narayan, Gayke Sanket Ramesh, Waghmare Sweeti Mohan
Email(s):
ushaadsul99@gmail.com
DOI:
10.52711/2231-5691.2026.00030 
Address:
Madhuri Sanjay Wable, Adsul Samruddhi Subhash, Omkar Bapurao Bramhane, Bhand Revannath Narayan, Gayke Sanket Ramesh, Waghmare Sweeti Mohan
Shantiniketan College of Pharmacy, Dhotre, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
Clinical studies are increasingly using medical imaging. AI tools and imaging biomarker calculation are later incorporated in the clinical trial setting to decrease radiological reading times and provide objectivity to the assessment of new therapy response. Clinical trial risk assessment is increasingly using artificial intelligence (AI) to increase efficiency and safety. 142 papers published between 2013 and 2024 were examined in this scoping review, with an emphasis on operational (n = 45), efficacious (n = 46), and safety (n = 55) risk prediction. For tasks including phase transition prediction, treatment impact estimation, and adverse drug event prediction, artificial intelligence (AI) approaches such as causal machine learning, deep learning (e.g., transformers, graph neural networks), and classical machine learning are employed. These techniques make use of a variety of data sources, including patient information, scholarly articles, clinical trial protocols, and molecular structures. Applications for large language models (LLMs) have increased recently; in 2023, they were used in 7 out of 33 research. While some models achieve excellent performance (AUROC up to 96%), difficulties are still, including selection bias, limited prospective research, and data quality issues. Notwithstanding these drawbacks, AI-based risk assessment has a lot of potential to revolutionise clinical trials, especially by enhancing risk-based monitoring systems. The final half of the 1.5–2.0 billion USD, 10–15-year development cycle for a single new medicine is spent on clinical trials. As a result, a failed clinical trial costs between 800 million and 1.4 billion USD, including the preclinical development expenses in addition to the trial's investment. Only one out of ten compounds that enter a clinical trial make it to market, which is due to poor recruiting and patient cohort selection strategies as well as ineffective patient monitoring during trials. We describe how current developments in artificial intelligence (AI) can be applied to improve trial success rates by reshaping important clinical trial design phases.
Cite this article:
Madhuri Sanjay Wable, Adsul Samruddhi Subhash, Omkar Bapurao Bramhane, Bhand Revannath Narayan, Gayke Sanket Ramesh, Waghmare Sweeti Mohan. Asian Journal of Pharmaceutical Research. 2026; 16(2):201-6. doi: 10.52711/2231-5691.2026.00030
Cite(Electronic):
Madhuri Sanjay Wable, Adsul Samruddhi Subhash, Omkar Bapurao Bramhane, Bhand Revannath Narayan, Gayke Sanket Ramesh, Waghmare Sweeti Mohan. Asian Journal of Pharmaceutical Research. 2026; 16(2):201-6. doi: 10.52711/2231-5691.2026.00030 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-2-15
REFERENCES:
1. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. Jama. 2014 Jan 22; 311(4):368-77.
2. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgraduate Medicine. 2011 Sep 1; 123(5): 194-204.
3. Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. Non-clinical studies in the process of new drug development-Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazilian Journal of Medical and Biological Research. 2016; 49(12): e5646.
4. Yank V, Rennie D. Reporting of informed consent and ethics committee approval in clinical trials. JAMA. 2002 Jun 5; 287(21): 2835-8.
5. Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurology. 2015 May 1; 72(5): 582- 8.
6. Sack R. Images of Nebuchadnezzar: The emergence of a legend. Susquehanna University Press; 2004.
7. Willett W, Skerrett PJ, Giovannucci EL. Eat, drink, and be healthy: the Harvard Medical School guide to healthy eating. Simon and Schuster; 2017 Sep 19.
8. Nabhan GP. Coming home to eat: The pleasures and politics of local foods. WW Norton & Company; 2002 Nov 17.
9. Shapiro P. Clean meat: how growing meat without animals will revolutionize dinner and the world. Simon and Schuster; 2024 Apr 9.
10. Collier R. Legumes, Lemons and Streptomycin: A short history of the clinical trial.
11. Baron JH. Sailors' scurvy before and after James Lind–a reassessment. Nutrition Reviews. 2009 Jun 1; 67(6): 315-32.
12. Nair A, Morsy MA, Jacob S. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Development Research. 2018 Dec; 79(8): 373-82.
13. DiPaolo JA. Relative difficulties in transforming human and animal cells in vitro. Journal of the National Cancer Institute. 1983 Jan 1; 70(1): 3-8.
14. Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. JACC: Basic to Translational Science. 2016 Apr; 1(3): 170-9.
15. Holbein MB. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators. Journal of Investigative Medicine. 2009 Aug; 57(6): 688- 94.
16. Kaplan AV, Baim DS, Smith JJ, Feigal DA, Simons M, Jefferys D, Fogarty TJ, Kuntz RE, Leon MB. Medical device development: from prototype to regulatory approval. Circulation. 2004 Jun 29; 109(25): 3068-72.
17. Garner RC, Lappin G. The phase 0 microdosing concept. British Journal of Clinical Pharmacology. 2006 Apr; 61(4): 367.
18. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clinical Pharmacology & Therapeutics. 2006 Sep; 80(3): 203- 15.
19. Banner Jr W. Pharmacokinetics and. Nursing Care of the Critically Ill Child. 2012 May 8: 67.
20. Denny KH, Stewart CW. Acute, subacute, subchronic, and chronic general toxicity testing for preclinical drug development. InA Comprehensive Guide to Toxicology in Nonclinical Drug Development. 2024 Jan 1 (pp. 149-171). Academic Press.
21. Storer BE. Design and Analysis of Phase I Clinical Trials. Biometrics. 1989 Sep 1: 925-37.
22. Almeida L, Azevedo B, Nunes T, Vaz-da-Silva M, Soares-da-Silva P. Why healthy subjects volunteer for phase I studies and how they perceive their participation?. European journal of clinical pharmacology. 2007 Nov; 63(11):1085-94.
23. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. Journal of Clinical Oncology. 2005 Jun 20; 23(18): 4162-71.
24. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. JNCI: Journal of the National Cancer Institute. 2009 May 20; 101(10):708-20.
25. Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021 Dec 21; 375.
26. Delgado A, Guddati AK. Clinical endpoints in oncology-a primer. American Journal of Cancer Research. 2021 Apr 15; 11(4): 1121.
27. Ruchalski K, Braschi-Amirfarzan M, Douek M, Sai V, Gutierrez A, Dewan R, Goldin J. A primer on RECIST 1.1 for oncologic imaging in clinical drug trials. Radiology: Imaging Cancer. 2021 May 14; 3(3): e210008.
28. Chen X, Ma K. Neoadjuvant therapy in lung cancer: what is most important: objective response rate or major pathological response?. Current Oncology. 2021 Oct 13; 28(5): 4129- 38.
29. McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, Hudson E, Panades M, Mathew T, Anand A, Persic M. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. The Lancet. 2024 Oct 19; 404(10462): 1525-35.
30. Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduction and Targeted Therapy. 2024 Jul 17; 9(1): 175.
31. Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IP, Hughes BG, Pointreau Y, Aksoy S. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2024 May 1; 25(5): 572-87.
32. Le Flohic E, Vrijens B, Hiligsmann M. The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: an overview. British Journal of Clinical Pharmacology. 2024 Aug; 90(8): 1984-2003.
33. Van Spall HG, Bastien A, Gersh B, Greenberg B, Mohebi R, Min J, Strauss K, Thirstrup S, Zannad F. The role of early-phase trials and real-world evidence in drug development. Nature Cardiovascular Research. 2024 Feb; 3(2): 110-7.
34. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024 Jan; 271(1): 141-76.
35. Mascarenhas-Melo F, Diaz M, Gonçalves MB, Vieira P, Bell V, Viana S, Nunes S, Paiva- Santos AC, Veiga F. An overview of biosimilars—development, quality, regulatory issues, and management in healthcare. Pharmaceuticals. 2024 Feb 11; 17(2): 235.
36. Miola AC, Espósito AC, Miot HA. Techniques for randomization and allocation for clinical trials. Jornal Vascular Brasileiro. 2025 Jan 13; 23: e20240046.
37. Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N. CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14; 389.
38. Hamamoto R, Komatsu M, Yamada M, Kobayashi K, Takahashi M, Miyake M, Jinnai S, Koyama T, Kouno N, Machino H, Takahashi S. Current status and future direction of cancer research using artificial intelligence for clinical application. Cancer Science. 2025 Feb; 116(2): 297-307.
39. Myslicka M, Kawala-Sterniuk A, Bryniarska A, Sudol A, Podpora M, Gasz R, Martinek R, Kahankova Vilimkova R, Vilimek D, Pelc M, Mikolajewski D. Review of the application of the most current sophisticated image processing methods for the skin cancer diagnostics purposes. Archives of Dermatological Research. 2024 Mar 6; 316(4): 99.
40. Stonebraker M, Pavlo A. What Goes Around Comes Around... And Around... ACM Sigmod Record. 2024 Jul 31; 53(2): 21-37.
41. Reddy S, Giri D, Patel R. Artificial intelligence-based distinction of actinic keratosis and seborrheic keratosis. Cureus. 2024 Apr 21; 16(4).
42. Sedano R, Solitano V, Vuyyuru SK, Yuan Y, Hanžel J, Ma C, Nardone OM, Jairath V. Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review. Therapeutic Advances in Gastroenterology. 2025 Feb; 18:17562848251321915.
43. Sedano R, Solitano V, Vuyyuru SK, Yuan Y, Hanžel J, Ma C, Nardone OM, Jairath V. Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review. Therapeutic Advances in Gastroenterology. 2025 Feb; 18:17562848251321915.
44. Beattie J, Neufeld S, Yang D, Chukwuma C, Gul A, Desai N, Jiang S, Dohopolski M. Utilizing large language models for enhanced clinical trial matching: a study on automation in patient screening. Cureus. 2024 May 10; 16(5).
45. Lee K, Liu Z, Mai Y, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Stolovitzky G, Schadt E. Optimizing clinical trial eligibility design using natural language processing models and real- world data: algorithm development and validation. JMIR AI. 2024 Jul 29; 3:e50800.